Friday, June 29, 2018

Ixekizumab safe in patients with psoriatic arthritis

Analysis of pooled data from three phase III trials (SPIRIT-P1, -P2, and -P3) reveals that ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, is a safe treatment for patients with active psoriatic arthritis (PsA), according to a study.

No comments:

Post a Comment

Forgetfulness a strong barrier to treatment adherence in lupus, vasculitis patients

While self-reported adherence to treatment appears to be high for both systemic lupus erythematosus and vasculitis, patient forgetfulness re...